Advanced search
Publication Cover
Autoimmunity Volume 53, 2020 - Issue 5
Submit an article Journal homepage
312
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease

Timothy HadleyDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; ;Transplant Services, Children’s Healthcare of Atlanta (CHOA), Atlanta, GA, USA
,
Scott GillespieDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA;
,
Hillary EspinozaTransplant Services, Children’s Healthcare of Atlanta (CHOA), Atlanta, GA, USA
,
Jarod PrinceDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA;
,
Henning Gronbaek
,
Shanmuganathan ChandrakasanDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA;
,
Subra KuguthasanDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA;
,
Vasantha L. KolachalaDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA;
&
Nitika A. GuptaDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; ;Transplant Services, Children’s Healthcare of Atlanta (CHOA), Atlanta, GA, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6171-4731
ORCID Icon show all
Pages 253-260 | Received 14 Dec 2019, Accepted 12 Apr 2020, Published online: 06 May 2020

References

  • Liberal R, Grant CR, Mieli-Vergani G, et al. Autoimmune hepatitis: a comprehensive review. J Autoimmun. 2013;41:126–139.
  • Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41(1):31–37.
  • Vergani D, Longhi MS, Bogdanos DP, et al. Autoimmune hepatitis. Semin Immunopathol. 2009;31(3):421–435.
  • Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375(25):2501–2502.
  • Bunchorntavakul C, Reddy KR. Diagnosis and management of overlap syndromes. Clin Liver Dis. 2015;19(1):81–97.
  • Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–938.
  • Zamani MR, Aslani S, Salmaninejad A, et al. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41.
  • Palle SK, Naik KB, McCracken CE, et al. Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis. Liver Int. 2019;39(5):976–984.
  • Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH? Semin Liver Dis. 2009;29(03):297–306.
  • Lee H, Stapp RT, Ormsby AH, et al. The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Am J Clin Pathol. 2010;133(3):430–437.
  • Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42(1):53–62.
  • Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2(7):625–631.
  • Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet. 2013;382(9902):1433–1444.
  • Aarslev K, Dige A, Greisen SR, et al. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scand J Gastroenterol. 2017;52(1):93–99.
  • Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis – a comprehensive review. J Hepatol. 2017;67(6):1298–1323.
  • Farh KK, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518(7539):337–343.
  • Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014;153(1):145–152.
  • Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–268.
  • Oikawa T, Takahashi H, Ishikawa T, et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int. 2007;57(8):485–492.
  • Silva J, Brito BS, Silva INN, et al. Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients. Biomed Res Int. 2019;2019:1–7.
  • Rojas-Feria M, Castro M, Suarez E, et al. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19(42):7327–7340.
  • Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290(1):72–79.
  • Annunziato F, Cosmi L, Galli G, et al. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol. 1999;65(5):691–699.
  • Liu L, Huang D, Matsui M, et al. Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3–/– mice with experimental autoimmune encephalomyelitis. J Immunol. 2006;176(7):4399–4409.
  • Dagan-Berger M, Feniger-Barish R, Avniel S, et al. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood. 2006;107(10):3821–3831.
  • Chow MT, Ozga AJ, Servis RL, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity. 2019;50(6):1498–1512. e1495.
  • Lammers KM, Lu R, Brownley J, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135(1):194–204 e193.
  • Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103(6):807–815.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.